Synapse
⌘+K
Synapse
PulseExploreClubsResearchersJournals
Instagram
HomeClubsExplore
May 25, 2004Neurology

Cholesterol and APOE genotype interact to influence Alzheimer disease progression

View Full Paper
Ask AI
Bookmark
Share

Authors

RERebecca M. EvansUniversity Hospitals Coventry and Warwickshire NHS TrustSHS. HuiMinistry of EducationAPAnthony J. PerkinsIndiana University Health

Discussion

Loading...

Member takes

Implication

Key Points

Key points are not available for this paper at this time.

Cite This Study

Evans et al. (2004) studied this question.

synapsesocial.com/papers/6a9048b585f80aee81dd7bd2https://doi.org/10.1212/01.wnl.0000125323.15458.3f
View Full Paper
Ask AI
Bookmark
Share

Also Consider

Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context:

  1. 1A 30-week randomized controlled trial of high-dose tacrine in patients with Alzheimer's disease. The Tacrine Study Group1994 · 1,008 citations
  2. 2A 30-Week Randomized Controlled Trial of High-Dose Tacrine in Patients With Alzheimer's Disease1994 · 977 citations
  3. 3Elevated Serum Total and LDL Cholesterol in Very Old Patients with Alzheimer’s Disease2001 · 81 citations
  4. 4Treatment outcome of tacrine therapy depends on apolipoprotein genotype and gender of the subjects with Alzheimer's disease1998 · 199 citations
  5. 5Serum cholesterol, <i>APOE genotype, and the risk of Alzheimer’s disease: A population-based study of African Americans</i>2000 · 210 citations